Former President and Chief Executive Officer · Black Diamond Therapeutics, Inc. (BDTX)

David Epstein

A named executive officer of Black Diamond Therapeutics in every fiscal year CompBrief holds from FY2019 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$2,019,206

Salary $412,300Stock awards $0

FY2022: $1,644,857

2nd of 4 named executive officers at Black Diamond Therapeutics by FY2023 total.

4 named officers on file for Black Diamond Therapeutics, FY2023

David Epstein’s pay file — $29

  • 5 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Black Diamond Therapeutics’s whole pay program stands against its peers

  • Black Diamond Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on BDTX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 24, 2024 (DEF 14A).

Free

Get David Epstein’s full pay file as a PDF — free

More than this page: up to 10 years of David’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

David Epstein compensation by year

Black Diamond Therapeutics Summary Compensation Table · all 5 fiscal years held
In US dollars, as Black Diamond Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019FY2020FY2021FY2022FY2023
Salary$428,904$507,825$538,201$554,350$412,300
Bonus$0$0$0$0$0
Stock awards$0$0$0$0$0
Option awards$2,728,815$3,030,428$4,235,494$759,775$1,049,520
Non-equity incentive$171,562$270,400$228,735$310,436$0
Pension and deferred compensation$0$0$0$0$0
All other$16,800$59,563$87,795$20,296$557,386
Total$3,346,081$3,868,216$5,090,225$1,644,857$2,019,206

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Black Diamond Therapeutics, Inc. DEF 14A filed April 24, 2024, accession 0001104659-24-051211, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Black Diamond Therapeutics, Inc. filed document, accession 0001104659-24-051211. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2024.

$3.3M
$3.9M
$5.1M
$1.6M
$2.0M
FY19
FY20
FY21
FY22
FY23
SalaryNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
Option56,252—$28.69
Option150,002—$3.79
Option5,806—$19.00
Option315,000—$2.92

Per the Outstanding Equity Awards at Fiscal Year-End table in Black Diamond Therapeutics, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Black Diamond Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Mark VellecaPresident and Chief Executive Officer$2,949,854
David Epstein · this pageFormer President and Chief Executive Officer$2,019,206
Fang NiChief Business Officer and Interim Chief Financial Officer$1,489,526
Sergey YurasovChief Medical Officer$1,233,684

Board service

Black Diamond Therapeutics board · FY2023–FY2024
Director compensation in US dollars, as Black Diamond Therapeutics reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2024———$3,939,067$3,939,067
FY2023—————

Each year as the company reported it in Black Diamond Therapeutics's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: Black Diamond Therapeutics pays directors a $40,000 cash retainer. As stated in Black Diamond Therapeutics's FY2024 proxy.

The full Black Diamond Therapeutics compensation record

free company brief

This page is one person within Black Diamond Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Black Diamond Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

David Epstein's compensation dossier · One-time report. No refunds.